Carl L. Gordon
Sits on 8 boards. Overboarded · 8 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 8
- Current seats
- 8
- Board service
- 15 years
- Director since
- 2023
15 years of board service in total across 8 boards, counting each seat separately. Longest: Compass Therapeutics Inc., 3 years.
Compass Therapeutics Inc.
Director
Adicet Bio Inc.
Director
Keros Therapeutics Inc.
Director
ArriVent BioPharma Inc.
Director
MBX Biosciences Inc.
Director
Scribe Therapeutics Inc.
Director
BlossomHill Therapeutics Inc.
Director
Electra Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 21, 2026 | Electra Therapeutics Inc. | Derivative conversion | +2,002,310 | — | — |
| Sep 21, 2026 | Electra Therapeutics Inc. | Derivative conversion | +1,087,934 | — | — |
| Sep 21, 2026 | Electra Therapeutics Inc. | Derivative conversion | +1,703,314 | — | — |
| Sep 21, 2026 | Electra Therapeutics Inc. | Open-market purchase | +333,333 | $15.00 | $4,999,995 |
| Sep 21, 2026 | Electra Therapeutics Inc. | Derivative conversion | +758,279 | — | — |
| Sep 21, 2026 | Electra Therapeutics Inc. | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Aug 10, 2026 | BlossomHill Therapeutics Inc. | Derivative conversion | +1,039,996 | — | — |
| Aug 10, 2026 | BlossomHill Therapeutics Inc. | Derivative conversion | +1,049,283 | — | — |
| Aug 10, 2026 | BlossomHill Therapeutics Inc. | Open-market purchase | +625,000 | $16.00 | $10,000,000 |
| Jul 27, 2026 | Scribe Therapeutics Inc. | Derivative conversion | +348,825 | — | — |
| Jul 27, 2026 | Scribe Therapeutics Inc. | Open-market purchase | +1,000,000 | $15.00 | $15,000,000 |
| Nov 21, 2025 | Keros Therapeutics Inc. | Sold back to the company | −140,057 | $17.75 | $2,486,012 |
| Nov 21, 2025 | Keros Therapeutics Inc. | Sold back to the company | −74,465 | $17.75 | $1,321,754 |
| Jun 4, 2025 | Keros Therapeutics Inc. | Grant or award | +5,250 | — | — |
| Apr 9, 2025 | Compass Therapeutics Inc. | Open-market sale | −3,571,428 | $1.59 | $5,678,571 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.